U.S. COVID-19 cases are once again rising after they fell in the wake of September’s Delta spike, Dr. Anthony Fauci said. The seven-day average of new cases recently surged by 11%. (CNBC Weekly)
In a Phase II study, the Bristol Myers Squibb/Janssen blood thinner milvexian reduced the rate of venous thromboembolism compared to a commonly used anticoagulant. The companies are aiming to develop a blood thinner with a lower risk of bleeding. (Endpoints News)
49-year-old Medidata co-founder Glen de Vries died in a small plane crash in New Jersey. De Vries also served as vice chairman of life sciences and healthcare at Dassault Systèmes. (CNN)
The high cost of Biogen’s Aduhelm may hike up standard monthly premiums for Medicare Part B beneficiaries by $21.60 in 2022. The Centers for Medicare & Medicaid Services announced it must plan for a potential increase in Medicare spending if Aduhelm is covered, though uncertainty remains. (STAT)
McKesson, Cardinal Health and AmerisourceBergen are facing a $95 billion trial in Washington state over the opioid epidemic. The trial is part of some 3,300 state and local lawsuits aiming to hold companies accountable for the opioid crisis. (Reuters)
